These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33083052)

  • 1. Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial.
    Ziemssen F; Hammer T; Grueb M; Mueller B; Berk H; Gamulescu MA; Voegeler J; Wachtlin J; Ocean Study Group
    J Ophthalmol; 2020; 2020():8652370. PubMed ID: 33083052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration.
    Silva R; Axer-Siegel R; Eldem B; Guymer R; Kirchhof B; Papp A; Seres A; Gekkieva M; Nieweg A; Pilz S;
    Ophthalmology; 2013 Jan; 120(1):130-9. PubMed ID: 23021093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study.
    Bandello F; Staurenghi G; Ricci F; Midena E; Viola F; Lupieri Sinibaldi T; Colombo L; Peruzzi E; Bassanini S
    Br J Ophthalmol; 2020 Jan; 104(1):64-73. PubMed ID: 31079057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
    Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
    Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
    Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA.
    Jia Y; Zhu C; Du J; Xiang Y; Chen Y; Wang W; Tao C
    PeerJ; 2019; 7():e7490. PubMed ID: 31497391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Medical Dictionary for Regulatory Activities (MedDRA) reporting of herpes simplex virus (HSV) adverse events in atopic dermatitis clinical trials.
    Tao RE; Pixley JN; Kontzias CL; Feldman SR
    Arch Dermatol Res; 2023 Dec; 316(1):41. PubMed ID: 38085296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
    Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
    Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study.
    Rakic JM; Leys A; Brié H; Denhaerynck K; Pacheco C; Vancayzeele S; Hermans C; Macdonald K; Abraham I
    Clin Ophthalmol; 2013; 7():1849-58. PubMed ID: 24092964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.
    Chakraborty D; Stewart MW; Sheth JU; Sinha TK; Boral S; Das A; Mondal S; Mukherjee A
    Ophthalmol Ther; 2021 Jun; 10(2):337-348. PubMed ID: 33864599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.
    Khurana RN; Kunimoto D; Yoon YH; Wykoff CC; Chang A; Maturi RK; Agostini H; Souied E; Chow DR; Lotery AJ; Ohji M; Bandello F; Belfort R; Li XY; Jiao J; Le G; Kim K; Schmidt W; Hashad Y;
    Ophthalmology; 2021 Jul; 128(7):1027-1038. PubMed ID: 33221326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS).
    Ma P; Pan X; Liu R; Qu Y; Xie L; Xie J; Cao L; Chen Y
    Front Pharmacol; 2022; 13():1017889. PubMed ID: 36467087
    [No Abstract]   [Full Text] [Related]  

  • 19. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.
    Lang GE; Berta A; Eldem BM; Simader C; Sharp D; Holz FG; Sutter F; Gerstner O; Mitchell P;
    Ophthalmology; 2013 Oct; 120(10):2004-12. PubMed ID: 23725735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study.
    Mitchell P; Sheidow TG; Farah ME; Mahmood S; Minnella AM; Eter N; Eldem B; Al-Dhibi H; Macfadden W; Parikh S; Dunger-Baldauf C; Mahgoub MM; Schmidt-Erfurth U;
    PLoS One; 2020; 15(6):e0233595. PubMed ID: 32492069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.